Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

BackgroundProgrammed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients is not well understood.MethodsThe pres...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Hui Tang, Ruixuan Geng, Xiuxiu Xu, Yingyi Wang, Jiaxin Zhou, Shulan Zhang, Lin Zhao, Mei Guan, Chunmei Bai
פורמט: Artigo
שפה:Inglês
יצא לאור: Frontiers Media S.A. 2022-05-01
סדרה:Frontiers in Immunology
נושאים:
programmed cell death-1
antinuclear antibody
anti-Ro52 antibody
antithyroid antibody
immune-related adverse events
גישה מקוונת:https://www.frontiersin.org/articles/10.3389/fimmu.2022.893179/full
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים